The Prostate Cancer Prevention Trial, or PCPT, is a study designed to see whether the drug finasteride (trade name Proscar) can prevent prostate cancer in men ages 55 and older. (See a summary of the protocol.)
In June 2003, the PCPT was stopped early because of a clear finding that finasteride reduced the incidence of prostate cancer. However, those trial participants who did develop prostate cancer while taking finasteride experienced a slightly higher incidence of high-grade tumors. Researchers analyzing the data have shown that because men taking finasteride have a reduced prostate size, this contributes to finding more high-grade tumors on biopsy. Additionally, researchers also found that high-grade cancer was detected earlier and in a less extensive stage in the finasteride group than in the placebo group.
Specimens from the PCPT biorepository are also available for research by qualified investigators. A Request For Applications (RFA) for access to these specimens is now online at http://swog.org/visitors/pcpt.
The links on the left of this page will take you to more detailed information about the trial and its results so far.
Prostate cancer is a critical public health problem: more than 200,000 men are diagnosed with prostate cancer in the United States each year and around 30,000 die of the disease.
This text may be reproduced or reused freely. Please credit the National Cancer Institute as the source. Any graphics may be owned by the artist or publisher who created them, and permission may be needed for their reuse.